Source comparison
CJC-1295 vs Other Recovery Research Peptides: Comparison
Researchers evaluating CJC-1295 help recovery research often compare it to other peptide protocols with overlapping recovery mechanisms. The table below outlines functional differences between the most studied peptides in athletic recovery research. | Peptide
This comparison does not assign a generated winner or score.
- Researchers evaluating CJC-1295 help recovery research often compare it to other peptide protocols with overlapping recovery mechanisms. The table below outlines functional differences between the most studied peptides in athletic recovery research.
- | Peptide | Primary Mechanism | Half-Life | Dosing Frequency | IGF-1 Elevation | Recovery Markers Improved | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH analog with albumin binding | 6–8 days | Twice weekly | 60–90% above baseline for 7–10 days | Muscle protein synthesis, CK clearance, glycogen restoration | Best for sustained anabolic environment. Extended half-life reduces injection frequency but limits flexibility in protocol adjustment || CJC-1295 (no DAC) | GHRH analog without albumin binding | 30 minutes | Daily | 30–50% elevation for 4–6 hours | Similar to DAC version but requires daily dosing | Higher compliance burden; often stacked with GHRP-2 or ipamorelin for synergistic GH release || BPC-157 | Synthetic gastric peptide fragment | 4–6 hours | Daily or twice daily | No direct IGF-1 effect | Tendon healing, ligament repair, inflammation reduction | Targets localized tissue repair rather than systemic anabolic signaling. Complementary to CJC-1295 rather
- CJC-1295 with DAC offers the longest action duration among GHRH analogs, making it the most practical option for protocols requiring sustained IGF-1 elevation without daily injections. However, its extended half-life also means slower clearance if side effects occur. Protocols using shorter-acting peptides allow faster washout and dose adjustment.